You are here

Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43HL123059-01A1
Agency Tracking Number: R43HL123059
Amount: $226,033.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
108 Eagle Trace Drive, Half Moon Bay, CA, 94019-2286
DUNS: 961937666
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 STEPHEN EMBURY
 (415) 203-0436
 shembury@gmail.com
Business Contact
 STEPHEN EMBURY
Phone: (415) 203-0436
Email: shembury@gmail.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a poorly treated debilitating condition for which we are developing a promising, new oral prophylactic therapy. A dire need exists for our drug, as millions of patients whohave inherited SCD world-wide, ~100,000 in the US, continue to suffer with episodic pain, disability, and premature death. Hydroxyurea treatment has clear-cut deficiencies, and many drugs under development target treatment rather than prevention of acute events. The cause of most SCD morbidity is abnormal blood flow, notably acute pain crises that result from stoppage of microvascular flow. Defective blood flow results from multiple pathophysiologies, includin several that areindependent of the paradigmatic sequence of deoxygenation -gt sickle hemoglobin polymerization -gt red cell sickling. Based on evidence that endothelial P-selectin is central to ongoing impairment and acute stoppage of flow, we are targeting thi

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government